Allostery Investments LP Takes $4.77 Million Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Allostery Investments LP purchased a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 284,517 shares of the company’s stock, valued at approximately $4,766,000. Centessa Pharmaceuticals accounts for 4.9% of Allostery Investments LP’s investment portfolio, making the stock its 2nd biggest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CNTA. GAMMA Investing LLC lifted its position in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC increased its holdings in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after purchasing an additional 5,316 shares during the last quarter. XTX Topco Ltd lifted its stake in Centessa Pharmaceuticals by 122.9% during the fourth quarter. XTX Topco Ltd now owns 22,680 shares of the company’s stock worth $380,000 after purchasing an additional 12,506 shares in the last quarter. Finally, Voya Investment Management LLC acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $497,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on CNTA. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim reissued a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Piper Sandler began coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an “overweight” rating and a $38.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $27.71.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CTO Tia L. Bush sold 11,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $185,460.00. Following the transaction, the chief technology officer now owns 121,503 shares of the company’s stock, valued at approximately $2,048,540.58. This trade represents a 8.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 14,656 shares of the business’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $12.29, for a total value of $180,122.24. Following the completion of the sale, the chief executive officer now directly owns 261,361 shares of the company’s stock, valued at $3,212,126.69. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 219,513 shares of company stock worth $3,576,685 over the last three months. Insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $13.50 on Friday. The company has a market cap of $1.80 billion, a P/E ratio of -8.82 and a beta of 1.53. The firm has a fifty day moving average price of $14.22 and a 200 day moving average price of $15.81. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 12 month low of $7.75 and a 12 month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. Sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.